BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li SY, Li J, Dong XH, Teng GG, Zhang W, Cheng H, Gao W, Dai Y, Zhang XH, Wang WH. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 2021;26:e12804. [PMID: 33860967 DOI: 10.1111/hel.12804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao W, Xu Y, Liu J, Wang X, Dong X, Teng G, Liu B, Dong J, Ge C, Ye H, Zhang X, Cheng H. A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies. Helicobacter 2023;28:e12947. [PMID: 36650673 DOI: 10.1111/hel.12947] [Reference Citation Analysis]
2 Xu X, He C, Zhu Y. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Front Microbiol 2022;13:998240. [DOI: 10.3389/fmicb.2022.998240] [Reference Citation Analysis]
3 Chen XX, Chen YX, Bi HX, Zhao X, Zhang LF, Liu JY, Shi YQ. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori. J Dig Dis 2022;23:568-76. [PMID: 36415112 DOI: 10.1111/1751-2980.13146] [Reference Citation Analysis]
4 Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China. Helicobacter 2022;27:e12918. [PMID: 35877765 DOI: 10.1111/hel.12918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen J, Li P, Huang Y, Guo Y, Ding Z, Lu H. Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis. Pathogens 2022;11:786. [DOI: 10.3390/pathogens11070786] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Grosso R, de-Paz M. Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations. Pharmaceutics 2022;14:1340. [DOI: 10.3390/pharmaceutics14071340] [Reference Citation Analysis]
7 Hu S, Zhang X, Li W, Chen L, Zhao W, Xu J, Ye W. Identification of multiple single-nucleotide variants for clinical evaluation of Helicobacter pylori drug resistance. Talanta 2022;243:123367. [DOI: 10.1016/j.talanta.2022.123367] [Reference Citation Analysis]